Jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet
Supported by Amgen, Inc.
This webcast is intended to improve care of patients with melanoma by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This webcast is designed to meet the educational needs of hematologists/oncologists, surgical oncologists, radiation oncologist, dermatologists and other health care professionals who diagnose, treat, and manage patients with melanoma.
As a result of participating in the activity, learners should be better able to:
Outline the role of T-VEC oncolytic viral therapy alone and/or in combination with other immunotherapeutic agents for malignant melanoma
Evaluate PD-1/PD-L1 interactions that contribute to better outcomes for patients with malignant melanoma
Conflict Of Interest Disclosure Policy
It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.
Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.
Keith Flaherty, MD Director, Henri & Belinda Termeer Center for Targeted Therapy Richard Saltonstall Chair in Oncology Massachusetts General Hospital Cancer Center Boston, MA
Dr. Flaherty discloses: Consultant: Ariad, Lilly USA, LLC, Novartis, and Roche
Ryan J. Sullivan, MD Division of Hematology/Oncology Massachusetts General Hospital Cancer Center Boston, MA
Dr. Sullivan discloses: Advisory Board/Consultant: Novartis, Prometheus Research Sponsorship: Adaptive Biotechnologies, Bristol Myers Squibb, Merck, and Prometheus
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:
Keith Flaherty, MD, discloses that he is a consultant for Ariad, Lilly USA, LLC, Novartis, and Roche.
Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet. The A. Webb Roberts Center for CME of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.
The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.
The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
NON-ENDORSEMENT OF PRODUCTS The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.
There are no fees for participating and receiving CME credit for this webcast. During the period July 7, 2016 through July 7, 2017, participants must read all of the material and study the educational webcast.
This webcast includes text, graphics, and may include multimedia features.
To obtain credit, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact the CME Provider at 214-820-2317.
A. Webb Roberts Center for CME of Baylor Health Care System observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support. To contact CME Provider, call 214-820-2317.